Free Trial

Akebia Therapeutics (AKBA) Competitors

Akebia Therapeutics logo
$3.03 +0.05 (+1.68%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$3.10 +0.07 (+2.31%)
As of 10/24/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AKBA vs. IMVT, XENE, CGON, RARE, AAPG, AMRX, ZLAB, BEAM, CNTA, and IRON

Should you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Immunovant (IMVT), Xenon Pharmaceuticals (XENE), CG Oncology (CGON), Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Amneal Pharmaceuticals (AMRX), Zai Lab (ZLAB), Beam Therapeutics (BEAM), Centessa Pharmaceuticals (CNTA), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry.

Akebia Therapeutics vs. Its Competitors

Akebia Therapeutics (NASDAQ:AKBA) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 3.0% of Akebia Therapeutics shares are held by company insiders. Comparatively, 1.8% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Akebia Therapeutics presently has a consensus price target of $6.75, suggesting a potential upside of 122.77%. Immunovant has a consensus price target of $28.78, suggesting a potential upside of 51.94%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Akebia Therapeutics is more favorable than Immunovant.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akebia Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
Immunovant
1 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.58

Immunovant has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -17.91%. Akebia Therapeutics' return on equity of 0.00% beat Immunovant's return on equity.

Company Net Margins Return on Equity Return on Assets
Akebia Therapeutics-17.91% N/A -13.47%
Immunovant N/A -80.99%-72.23%

Akebia Therapeutics has higher revenue and earnings than Immunovant. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akebia Therapeutics$203.73M3.94-$69.41M-$0.17-17.82
ImmunovantN/AN/A-$413.84M-$2.85-6.65

In the previous week, Akebia Therapeutics had 3 more articles in the media than Immunovant. MarketBeat recorded 8 mentions for Akebia Therapeutics and 5 mentions for Immunovant. Akebia Therapeutics' average media sentiment score of 0.69 beat Immunovant's score of 0.60 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akebia Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Immunovant
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Akebia Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

Summary

Akebia Therapeutics beats Immunovant on 11 of the 15 factors compared between the two stocks.

Get Akebia Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AKBA vs. The Competition

MetricAkebia TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$790.13M$3.02B$6.24B$10.69B
Dividend YieldN/A57.75%5.72%4.82%
P/E Ratio-17.8227.5331.2830.77
Price / Sales3.94613.00563.45174.94
Price / CashN/A168.3237.0861.44
Price / Book-13.175.6512.056.61
Net Income-$69.41M$33.06M$3.33B$277.10M
7 Day Performance3.41%3.16%1.93%2.56%
1 Month Performance11.81%8.14%7.77%3.77%
1 Year Performance90.57%-2.49%56.40%33.01%

Akebia Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AKBA
Akebia Therapeutics
3.5136 of 5 stars
$3.03
+1.7%
$6.75
+122.8%
+91.8%$790.13M$203.73M-17.82430Analyst Forecast
IMVT
Immunovant
1.977 of 5 stars
$19.22
+9.8%
$28.78
+49.7%
-37.9%$3.35BN/A-6.74120News Coverage
XENE
Xenon Pharmaceuticals
2.5086 of 5 stars
$43.44
+4.3%
$53.67
+23.5%
-2.6%$3.35B$9.43M-12.24210
CGON
CG Oncology
2.1026 of 5 stars
$43.59
+5.1%
$58.82
+34.9%
+19.8%$3.32B$1.14M-24.6361Analyst Forecast
RARE
Ultragenyx Pharmaceutical
4.3755 of 5 stars
$34.40
+5.4%
$81.50
+136.9%
-38.8%$3.32B$560.23M-6.221,294News Coverage
Analyst Forecast
Gap Up
AAPG
Ascentage Pharma Group International
N/A$35.31
-0.4%
N/AN/A$3.29B$390.60M0.00600Positive News
AMRX
Amneal Pharmaceuticals
2.3952 of 5 stars
$10.24
+3.2%
$12.00
+17.2%
+27.0%$3.22B$2.79B1,025.038,100Analyst Forecast
ZLAB
Zai Lab
2.7341 of 5 stars
$28.74
+1.6%
$56.35
+96.1%
-20.7%$3.21B$398.99M-14.091,869News Coverage
Analyst Forecast
Analyst Revision
BEAM
Beam Therapeutics
3.6132 of 5 stars
$30.62
+17.9%
$45.92
+50.0%
+26.6%$3.10B$63.52M-6.80510News Coverage
Analyst Forecast
High Trading Volume
CNTA
Centessa Pharmaceuticals
3.4951 of 5 stars
$22.79
-1.0%
$32.38
+42.1%
+55.8%$3.05B$15M-12.73200News Coverage
Analyst Forecast
IRON
Disc Medicine
2.8426 of 5 stars
$87.17
-3.1%
$108.73
+24.7%
+86.2%$3.03BN/A-19.5030Trending News
Analyst Forecast
Analyst Revision
High Trading Volume

Related Companies and Tools


This page (NASDAQ:AKBA) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners